Evidence map›Paper›PMID 37469991›Full record

ArticleBioMed research international2023

Preclinical Demonstration of a Novel Treatment with High Efficacy and No Detectable Toxicity for Inflammatory Skin Conditions including Psoriasis.

John P Vanden Heuvel, Shuling Zhou, Anisha B Patel, Harry N Kamerow, Peter Baran, John P Ford

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

John P Vanden HeuvelDepartment of Veterinary and Biomedical Sciences, Penn State University, University Park, PA 16802, USA.ORCID https://orcid.org/0000-0002-3350-2037
Shuling ZhouDepartment of Veterinary and Biomedical Sciences, Penn State University, University Park, PA 16802, USA.
Anisha B PatelAsymmetric Therapeutics LLC, 141 Main St., P.O. Box J, Unadilla, NY 13849, USA.ORCID https://orcid.org/0000-0002-5372-784X
Harry N KamerowMount Nittany Medical Center, 1850 East Park Avenue, State College, PA 16803, USA.
Peter BaranMount Nittany Medical Center, 1850 East Park Avenue, State College, PA 16803, USA.
John P FordAsymmetric Therapeutics LLC, 141 Main St., P.O. Box J, Unadilla, NY 13849, USA.ORCID https://orcid.org/0000-0001-5151-4157
Mount Nittany Medical Center · USPennsylvania State University · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the management options for psoriasis have progressed with the use of systemic agents, there are few efficacious nonsteroidal topical therapies for patients with limited or lower grade disease. The effects of allopurinol (Allo) and glutathione (GSH) were examined in two different

Indexed as

PsoriasisCell ProliferationHumansKeratinocytesMethotrexateSkinTumor Necrosis Factor-alphaMethotrexateTumor Necrosis Factor-alpha

Identifiers

PMID37469991
PMCPMC10353900
OpenAlexW4383957252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.